T-cell therapy in the treatment of post-transplant lymphoproliferative disease

被引：175

作者：

Bollard, Catherine M. ^{[1
,2
,3
]}

Rooney, Cliona M. ^{[1
,2
,3
]}

Heslop, Helen E. ^{[1
,2
,3
]}

机构：

[1] Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Dept Pediat, Houston, TX 77030 USA

[2] Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Dept Med, Houston, TX 77030 USA

[3] Texas Childrens Hosp, Houston, TX 77030 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2012年 / 9卷 / 09期

关键词：

EPSTEIN-BARR-VIRUS; ORGAN TRANSPLANT RECIPIENTS; VERSUS-HOST-DISEASE; ADOPTIVE TRANSFER; PERIPHERAL-BLOOD; LIVER-TRANSPLANT; BTS GUIDELINES; HIGH-RISK; EBV; LYMPHOCYTES;

D O I：

10.1038/nrclinonc.2012.111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.

引用

页码：510 / 519

页数：10

共 80 条

[1] Lymphoproliferative Disorders and De Novo Malignancies in Intestinal and Multivisceral Recipients: Improved Outcomes With New Outlooks [J].

Abu-Elmagd, Kareem M. ;

Mazariegos, George ;

Costa, Guilherme ;

Soltys, Kyle ;

Bond, Geoffrey ;

Sindhi, Rakesh ;

Green, Michael ;

Jaffe, Ronald ;

Wu, Tong ;

Koritsky, Darlene ;

Matarese, Laura ;

Schuster, Bonnie ;

Martin, Lillian ;

Dvorchik, Igor ;

Nalesnik, Michael A. .

TRANSPLANTATION, 2009, 88 (07) :926-934

[2] Allo-HLA reactivity of virus-specific memory T cells is common [J].

Amir, Avital L. ;

D'Orsogna, Lloyd J. A. ;

Roelen, Dave L. ;

van Loenen, Marleen M. ;

Hagedoorn, Renate S. ;

de Boer, Renate ;

van der Hoorn, Menno A. W. G. ;

Kester, Michel G. D. ;

Doxiadis, Ilias I. N. ;

Falkenburg, J. H. Frederik ;

Claas, Frans H. J. ;

Heemskerk, Mirjam H. M. .

BLOOD, 2010, 115 (15) :3146-3157

[3] Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients [J].

Babcock, GJ ;

Decker, LL ;

Freeman, RB ;

Thorley-Lawson, DA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (04) :567-576

[4] Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes [J].

Barker, Juliet N. ;

Doubrovina, Ekaterina ;

Sauter, Craig ;

Jaroscak, Jennifer J. ;

Perales, Miguel A. ;

Doubrovin, Mikhail ;

Prockop, Susan E. ;

Koehne, Guenther ;

O'Reilly, Richard J. .

BLOOD, 2010, 116 (23) :5045-5049

[5] Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer [J].

Bollard, Catherine M. ;

Gottschalk, Stephen ;

Leen, Ann M. ;

Weiss, Heidi ;

Straathof, Karin C. ;

Carrum, George ;

Khalil, Mariam ;

Wu, Meng-fen ;

Huls, M. Helen ;

Chang, Chung-Che ;

Gresik, M. Victoria ;

Gee, Adrian P. ;

Brenner, Malcolm K. ;

Rooney, Cliona M. ;

Heslop, Helen E. .

BLOOD, 2007, 110 (08) :2838-2845

[6] Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity [J].

Bollard, CM ;

Rössig, C ;

Calonge, MJ ;

Huls, MH ;

Wagner, HJ ;

Massague, J ;

Brenner, MK ;

Heslop, HE ;

Rooney, CM .

BLOOD, 2002, 99 (09) :3179-3187

[7] Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease [J].

Brewin, Jennifer ;

Mancao, Christoph ;

Straathof, Karin ;

Karlsson, Helen ;

Samarasinghe, Sujith ;

Amrolia, Persis J. ;

Pule, Martin .

BLOOD, 2009, 114 (23) :4792-4803

[8] Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation [J].

Brunstein, Claudio G. ;

Weisclorf, Daniel J. ;

DeFor, Todd ;

Barker, Juliet N. ;

Tolar, Jakub ;

van Burik, Jo-Anne H. ;

Wagner, John E. .

BLOOD, 2006, 108 (08) :2874-2880

[9] AN ALLORESPONSE IN HUMANS IS DOMINATED BY CYTOTOXIC T-LYMPHOCYTES (CTL) CROSS-REACTIVE WITH A SINGLE EPSTEIN-BARR-VIRUS CTL EPITOPE - IMPLICATIONS FOR GRAFT-VERSUS-HOST DISEASE [J].

BURROWS, SR ;

KHANNA, R ;

BURROWS, JM ;

MOSS, DJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (04) :1155-1161

[10] A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease [J].

Carpenter, PA ;

Appelbaum, FR ;

Corey, L ;

Deeg, HJ ;

Doney, K ;

Gooley, T ;

Krueger, J ;

Martin, P ;

Pavlovic, S ;

Sanders, J ;

Slattery, J ;

Levitt, D ;

Storb, R ;

Woolfrey, A ;

Anasetti, C .

BLOOD, 2002, 99 (08) :2712-2719

← 1 2 3 4 5 6 7 8 →